Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - NIAID - Additional Information (Details)

v3.8.0.1
Licensing and Other Arrangements - NIAID - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2008
Dec. 31, 2017
Mar. 31, 2018
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Unearned revenue recognized under units-of-revenue method – non-current   $ 17,123 [1] $ 17,019  
National Institute of Allergy and Infectious Diseases "NIAID" [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contract liabilities   800 $ 800  
National Institute of Allergy and Infectious Diseases "NIAID" [Member] | Arrangement with Governmental Agency 2 [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total contract amount awarded $ 64,800      
Contracts revenue wrote off   $ 400    
National Institute of Allergy and Infectious Diseases "NIAID" [Member] | Arrangement with Governmental Agency 3 [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contractual term 3 years      
Accounts receivable       $ 400
Unearned revenue recognized under units-of-revenue method – non-current       $ 800
[1] The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.